Back to Search
Start Over
Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: A Population-Based Study
Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: A Population-Based Study
- Source :
- Clinical Genitourinary Cancer. 17:231-237.e2
- Publication Year :
- 2019
- Publisher :
- Elsevier BV, 2019.
-
Abstract
- Purpose To investigate clinicopathologic characteristics and cancer-specific mortality (CSM) rates of ductal carcinoma (DC) versus the common acinar adenocarcinoma in nonmetastatic and metastatic (M1) prostate cancer patients. Patients and Methods Within the Surveillance, Epidemiology, and End Results database (2004-2015), we identified patients with histologically confirmed prostate adenocarcinoma who harbored either DC (n = 581) or acinar adenocarcinoma (n = 489,296). Kaplan-Meier and 4:1 propensity score–matched multivariable Cox regression models adjusted for clinical and pathologic parameters were used to test for CSM differences. Three separate analyses were performed on all patients with nonmetastatic disease, patients with nonmetastatic patients treated with radical prostatectomy only, and patients with metastatic disease. Results DC was identified in 502 (0.10%) of 469,946 patients with nonmetastatic disease and 79 (0.39%) of 19,931 patients with metastatic disease. In patients with nonmetastatic disease, 253 (50.4%) DC patients underwent radical prostatectomy, 61 (12.2%) DC patients received external-beam radiotherapy, and 188 (37.4%) received other treatment modalities. In multivariable analyses, DC was associated with higher CSM in the overall nonmetastatic patient population (hazard ratio [HR] = 1.8; 95% confidence interval [CI], 1.3-2.6; P = .001), in the nonmetastatic radical prostatectomy population (HR = 2.8; 95% CI, 1.3-6.0; P Conclusion Prostate cancers of ductal origin represent a rare entity among patients with nonmetastatic disease as well as among patients with metastatic disease, and regardless of stage, DC behaves more aggressively.
- Subjects :
- Male
Oncology
medicine.medical_specialty
Urology
medicine.medical_treatment
Population
030232 urology & nephrology
Acinar adenocarcinoma
Metastatic disease
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Internal medicine
medicine
Humans
Stage (cooking)
education
Aged
Neoplasm Staging
Prostatectomy
education.field_of_study
Radiotherapy
Carcinoma, Acinar Cell
business.industry
Proportional hazards model
Hazard ratio
Cancer-specific mortality
Prostatic Neoplasms
Middle Aged
Ductal carcinoma
medicine.disease
Survival Analysis
SEER database
Carcinoma, Ductal
Treatment Outcome
030220 oncology & carcinogenesis
Regression Analysis
Infiltrating ductal
business
SEER Program
Subjects
Details
- ISSN :
- 15587673
- Volume :
- 17
- Database :
- OpenAIRE
- Journal :
- Clinical Genitourinary Cancer
- Accession number :
- edsair.doi.dedup.....e36ae2136d596c4cc4f376dbe26717d5
- Full Text :
- https://doi.org/10.1016/j.clgc.2019.04.009